| Outcome Measures: |
Primary: Change From Baseline in Post-Prandial Glucose Area Under the Concentration-Time Curve From Time 2 to 6 Hours (AUC 2-6) After a Mixed Meal Tolerance Test (MMTT) at Day 28, Change from baseline in post-prandial area under the plasma glucose concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC., Baseline (Day -1); 2 to 6 hours post-dose on Day 28 | Secondary: Change From Baseline in 24-Hour Average Plasma Glucose (APG) Post-Dose at Day 28, APG= AUC (0-24)/24. AUC (0-24) was computed using Linear trapezoidal method., Baseline (Day -1); 24 hours post-dose on Day 28|Change From Baseline in Post-Prandial Insulin Area Under the Concentration-Time Curve From Time 2 to 6 Hours (AUC 2-6) After a Mixed Meal Tolerance Test (MMTT) at Day 28, Change from baseline in post-prandial plasma insulin AUC under the plasma insulin concentration versus time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC., Baseline (Day -1); 2 to 6 hours post-dose on Day 28|Change From Baseline in Post-Prandial C-Peptide Area Under the Concentration-Time Curve From Time 2 to 6 Hours (AUC 2-6) After a Mixed Meal Tolerance Test (MMTT) at Day 28, Change from baseline in post-prandial area under the plasma C-peptide concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC., Baseline (Day -1); 2 to 6 hours post-dose on Day 28|Change From Baseline in Post-Prandial Net Triglyceride Area Under the Concentration-Time Curve From Time 2 to 6 Hours (AUC 2-6) After a Mixed Meal Tolerance Test (MMTT) at Day 28, Change from baseline in post-prandial area under the plasma net triglyceride concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC., Baseline (Day -1); 2 to 6 hours post-dose on Day 28|Change From Baseline in Total Amide Glucagon Like Peptide-1 (GLP-1) and Active Glucagon Like Peptide-1 (GLP-1) Area Under the Concentration-Time Curve From Time 2 to 6 Hours (AUC 2-6) at Day 28, Change from baseline in total amide GLP-1 and active GLP-1 area under the plasma concentration time curve was computed by Linear trapezoidal method., Baseline (Day -1); 2 to 6 hours post-dose on Day 28|Change From Baseline in Gastric Inhibitory Peptide (GIP) Area Under the Concentration-Time Curve From Time 2 to 6 Hours (AUC 2-6) at Day 28, Change from baseline in GIP area under the plasma concentration time curve was computed by Linear trapezoidal method., Baseline (Day -1); 2 to 6 hours post-dose on Day 28|Change From Baseline in Peptide YY (PYY) Area Under the Concentration-Time Curve From Time 2 to 6 Hours (AUC 2-6) at Day 28, Change from baseline in PYY area under the plasma concentration time curve was computed by Linear trapezoidal method., Baseline (Day -1); 2 to 6 hours post-dose on Day 28|Change From Baseline in Fasting Glucose at Day 28, 0 hour (pre-dose) on Day -1, Day 28|Change From Baseline in Fasting Insulin at Day 28, 0 hour (pre-dose) on Day -1, Day 28|Change From Baseline in Fasting Net Triglycerides at Day 28, 0 hour (pre-dose) on Day -1, Day 28|Change From Baseline in Post-Lunch Glucose Excursions Area Under the Concentration-Time Curve From Time 6 to 10 Hours (AUC 6-10) Post-dose at Day 28, Change from baseline in post-lunch glucose excursion under the plasma concentration time curve was computed by Linear trapezoidal method., Baseline (Day -1); 6 to 10 hours post-dose on Day 28|Change From Baseline in Post-Dinner Glucose Excursions Area Under the Concentration-Time Curve From Time 12 to 16 Hours (AUC 12-16) Post-dose at Day 28, Change from baseline in post-dinner glucose excursion under the plasma concentration time curve was computed by Linear trapezoidal method., Baseline (Day -1); 12 to 16 hours post-dose on Day 28|Maximum Observed Plasma Concentration (Cmax) of PF-04620110, 24 hours post-morning dose on Day 28|Minimum Observed Plasma Trough Concentration (Cmin) of PF-04620110, 24 hours post-morning dose on Day 28|Time to Cmax (Tmax) of PF-04620110, 24 hours post-morning dose on Day 28|Area Under the Concentration-Time Curve AUC (0-24) of PF-04620110, Area under the plasma concentration-time curve from time 0 (pre-dose) to 24 hours. AUC (0-24) was computed using the linear trapezoidal method., 24 hours post-morning dose on Day 28
|
| Locations: |
Pfizer Investigational Site, Chula Vista, California, 91911, United States|Pfizer Investigational Site, DeLand, Florida, 32720, United States|Pfizer Investigational Site, Miami Gardens, Florida, 33169, United States
|
